OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
43,850
+1,750 (4.16%)
Mar 28, 2025, 3:30 PM KST
160.70%
Market Cap 816.84B
Revenue (ttm) 5.68B
Net Income (ttm) -40.66B
Shares Out 18.63M
EPS (ttm) -2,414.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 425,362
Average Volume 1,286,465
Open 42,100
Previous Close 42,100
Day's Range 41,200 - 44,200
52-Week Range 8,280 - 64,000
Beta 0.57
RSI 51.39
Earnings Date Mar 19, 2025

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2024, OliX Pharmaceuticals's revenue was 5.68 billion, a decrease of -66.73% compared to the previous year's 17.06 billion. Losses were -40.66 billion, 112.9% more than in 2023.

Financial Statements

News

There is no news available yet.